The investigation of immune-related biomarkers for tumor immunotherapy represents a rapidly evolving and highly promising research frontier. While the ECT2 gene has been implicated in the progression of diverse malignancies, its pan-cancer implications and underlying molecular mechanisms remain insufficiently characterized. Building upon emerging evidence that suggests an association between ECT2 and tumor pathogenesis, our study endeavors to comprehensively elucidate the prognostic significance and immunological attributes of ECT2 in oncogenesis. Through integrative analysis of comprehensive genomic datasets derived from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) repositories, we systematically examined the oncogenic potential of ECT2 across human malignancies. Our findings demonstrate substantial upregulation of ECT2 expression in 31 distinct tumor types, with pan-cancer Cox regression analyses revealing statistically significant correlations between elevated ECT2 expression and adverse clinical outcomes, including reduced overall survival (OS), disease-specific survival (DSS), disease-free interval (DFS), and progression-free interval (PFI) across multiple cancer subtypes. To further validate the functional implications of ECT2 in tumor biology, we employed hepatocellular carcinoma (HCC) cell line HepG2 as an experimental model. Utilizing shRNA-mediated gene silencing, we observed marked reduction in cellular viability upon ECT2 knockdown. Immunofluorescence analyses corroborated these findings, demonstrating diminished expression of cell cycle regulatory proteins, particularly Cyclin D1, following ECT2 suppression. RNA sequencing analysis of ECT2-depleted HepG2 cells identified significant enrichment of differentially expressed genes in cell cycle regulation and proliferative signaling pathways, providing mechanistic insights into ECT2’s tumor-promoting effects. Our comprehensive pan-cancer analysis further revealed significant associations between ECT2 expression patterns and key immunological parameters, including immune cell infiltration, immune checkpoint molecule expression, tumor mutational burden (TMB), and microsatellite instability (MSI) status across various malignancies. Functional pathway analysis implicated ECT2 in critical mitotic cell cycle processes, offering novel perspectives on its role in cancer initiation and metastatic progression across diverse tumor types. These findings collectively contribute to our understanding of ECT2 as a potentially critical regulator in oncogenesis, with implications for both tumor biology and therapeutic development. The multifaceted role of ECT2 in cancer progression, as revealed through our integrative analysis, underscores its potential as both a prognostic biomarker and therapeutic target in cancer immunotherapy.